Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZITHROMYCIN vs BRISTAMYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting m RNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.
BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Acute bacterial exacerbations of chronic obstructive pulmonary disease due to H. influenzae, M. catarrhalis, or S. pneumoniae,Acute bacterial sinusitis due to H. influenzae, M. catarrhalis, or S. pneumoniae,Community-acquired pneumonia due to C. pneumoniae, H. influenzae, M. pneumoniae, or S. pneumoniae,Pharyngitis/tonsillitis due to S. pyogenes,Uncomplicated skin and skin structure infections due to S. aureus, S. pyogenes, or S. agalactiae,Urethritis/cervicitis due to C. trachomatis or N. gonorrhoeae,Genital ulcer disease due to H. ducreyi,Acute otitis media due to H. influenzae, M. catarrhalis, or S. pneumoniae,Prevention of disseminated M. avium complex disease in advanced HIV infection,Pertussis (off-label)
Treatment of infections caused by susceptible gram-positive bacteria,Prophylaxis of bacterial endocarditis in dental procedures,Off-label: treatment of anthrax,Off-label: treatment of Lyme disease
500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.
500 mg intravenously every 6 hours. Infuse over 60 minutes.
Terminal half-life of approximately 68 hours (range 35–96 h) after multiple doses, allowing once-daily dosing and a prolonged post-antibiotic effect.
Terminal elimination half-life: 6–8 hours (prolonged to 20–40 hours in severe renal impairment; dose adjustment required for Cr Cl <30 m L/min).
Primarily hepatic, not via cytochrome P450 system. Partially metabolized to inactive metabolites. Eliminated via biliary excretion and renal excretion (<15% unchanged).
Primarily renal excretion; minor hepatic metabolism via hydrolysis to penicilloic acid.
Primarily biliary/fecal (approx. 50% unchanged); renal excretion accounts for about 12% of the dose.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5% as unchanged drug and metabolites.
7–51% (concentration-dependent); primarily binds to albumin.
80–85% primarily to albumin; minor binding to α1-acid glycoprotein.
31.1 L/kg (range 23–50 L/kg), indicating extensive tissue penetration and sequestration (e.g., WBCs, liver, lung).
0.3–0.5 L/kg, indicating limited extravascular distribution; higher in neonates and patients with edema.
Oral: 37–40% (fasting); food may decrease absorption by ~50%.
Oral: 60–80% (variable, reduced by food); IM: near 100%.
No dose adjustment required for GFR ≥10 m L/min. For GFR <10 m L/min, caution advised; no specific dose recommendation, consider alternative agent.
Cr Cl >60 m L/min: no adjustment; Cr Cl 30-60 m L/min: 500 mg every 8 hours; Cr Cl 15-29 m L/min: 500 mg every 12 hours; Cr Cl <15 m L/min: 500 mg every 24 hours; on hemodialysis: 500 mg every 24 hours, give after dialysis.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A and B). Contraindicated in severe hepatic impairment (Child-Pugh class C).
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg every 6 hours; Child-Pugh C: 250 mg every 12 hours.
For otitis media and community-acquired pneumonia: 10 mg/kg orally or IV on day 1 (max 500 mg), then 5 mg/kg (max 250 mg) once daily on days 2-5. For pharyngitis/tonsillitis: 12 mg/kg orally once daily for 5 days (max 500 mg/day).
Age <1 month: 30 mg/kg/day intravenously divided every 12 hours; Age 1 month to 12 years: 15-20 mg/kg intravenously every 6 hours; Max 1.5 g/day.
No specific dose adjustment required; use same dosing as younger adults. Monitor renal function due to age-related decline, but no modification needed unless severe renal impairment (Cr Cl <10 m L/min).
No specific dosage adjustment beyond renal function; monitor renal function and adjust per Cr Cl as in renal_adjustment; consider increased risk of nephrotoxicity and neurotoxicity.
None.
Patients with a history of immediate hypersensitivity reactions to penicillins or cephalosporins may experience severe anaphylaxis. Resuscitative equipment should be available during administration.
Hepatotoxicity: hepatitis, cholestatic jaundice, hepatic necrosis, hepatic failure,QT prolongation and torsades de pointes (especially with concurrent use of other QT-prolonging agents, electrolyte abnormalities, bradycardia, or structural heart disease),Clostridioides difficile-associated diarrhea (CDAD),Aggravation of myasthenia gravis,Severe allergic reactions (angioedema, anaphylaxis, Stevens-Johnson syndrome),Infantile hypertrophic pyloric stenosis (IHPS) in neonates following oral azithromycin,Use in pregnancy: category B; avoid during breastfeeding due to potential for disruption of infant gut flora
Monitor renal function in patients with renal impairment; risk of superinfection with prolonged use; use caution in patients with history of allergies.
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,History of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use,Concurrent use with ergotamine or dihydroergotamine (possible ergot toxicity)
Hypersensitivity to penicillins or cephalosporins; history of immediate-type hypersensitivity reactions to beta-lactam antibiotics.
Food does not significantly affect absorption; can be taken with or without food. However, avoiding high-fat meals may reduce minor GI side effects. No known specific food interactions.
No specific food interactions. Alcohol should be avoided due to risk of disulfiram-like reaction (headache, nausea, flushing).
FDA Category B. No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No significant association with birth defects. Second/third trimester: No reported fetal harm from short-term use for infections like chorioamnionitis. Use only if clearly needed.
BRISTAMYCIN is contraindicated in all trimesters due to dose-dependent teratogenicity. First trimester: high risk of major congenital malformations, including neural tube defects, cleft palate, and cardiac anomalies. Second trimester: increased risk of fetal growth restriction and neurodevelopmental toxicity. Third trimester: risk of preterm birth, low birth weight, and neonatal toxicity (hypotension, renal impairment, pulmonary hypertension).
Azithromycin is excreted into breast milk in low amounts. M/P ratio approximately 0.2-0.6. Relative infant dose estimated at 2-6% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding; monitor infant for diarrhea or rash.
BRISTAMYCIN is excreted into human breast milk with an M/P ratio of 1.5. Significant infant exposure may occur. Breastfeeding is contraindicated due to risks of neonatal toxicity, including hypotension, renal dysfunction, and potential neurodevelopmental effects. Use of expressed breast milk is not recommended during therapy and for 2 weeks after last dose.
No dose adjustment required for pregnancy. Standard adult dosing (500 mg on day 1, then 250 mg daily for 4 days) is appropriate. Note: Pregnancy may increase volume of distribution, but pharmacokinetic studies suggest no significant decrease in AUC; no need for dose increase.
Pregnancy reduces systemic bioavailability of BRISTAMYCIN due to increased plasma volume and enhanced renal clearance. To maintain therapeutic levels, the dose should be increased by 25% in the second trimester and 35% in the third trimester. Postpartum, dose should be reduced to prepregnancy levels within 48 hours after delivery. Therapeutic drug monitoring is strongly recommended.
Monitor for QTc prolongation especially in patients with preexisting cardiac conditions or those on other QT-prolonging drugs. Azithromycin has a long half-life (68 hours) allowing for shorter treatment courses. Use with caution in hepatic impairment; consider alternative in severe liver disease. Not recommended for pneumonia in patients with bacteremia due to increased mortality risk. Administer on an empty stomach or with food if GI upset occurs; however, absorption is unaffected by food.
BRISTAMYCIN is a cephalosporin antibiotic with activity against Gram-positive and some Gram-negative bacteria. Administer IV over 30 minutes to reduce infusion-related phlebitis. Monitor renal function in elderly or nephrotoxic co-administration. Cross-allergenicity with penicillins occurs in ~5% of patients.
Take exactly as prescribed; do not skip doses or stop early even if you feel better.,Do not take antacids containing aluminum or magnesium within 2 hours before or after this medication.,Report any signs of liver problems (nausea, vomiting, dark urine, jaundice) or severe diarrhea (watery or bloody) immediately.,Azithromycin may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Inform your doctor if you have a history of QT prolongation, heart rhythm problems, or electrolyte imbalances.,Store at room temperature away from moisture and heat; discard any unused liquid after 10 days.
Complete the full course of therapy even if you feel better.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,Avoid alcohol during treatment and for 48 hours after to prevent disulfiram-like reactions.,Inform your doctor if you have kidney disease or are taking anticoagulants.
"Azithromycin, a macrolide antibiotic, is known to prolong the QT interval by blocking cardiac potassium channels (specifically IKr), which can lead to torsades de pointes. Mifepristone also poses a risk of QT prolongation, likely via similar mechanisms. Coadministration may result in additive QTc prolongation, increasing the risk of life-threatening ventricular arrhythmias, especially in patients with preexisting cardiac conditions or electrolyte disturbances."
"Lumiracoxib is a selective COX-2 inhibitor primarily metabolized by CYP2C9 and to a lesser extent by CYP3A4. Azithromycin, a macrolide antibiotic, is a known inhibitor of CYP3A4. Concomitant use may decrease the metabolism of azithromycin, leading to increased plasma concentrations and potential toxicity, such as QT prolongation and hepatotoxicity. Elevated azithromycin levels can also enhance its antibacterial effects but raise safety concerns."
"Azithromycin, a macrolide antibiotic, inhibits the cardiac potassium channel encoded by hERG (human Ether-à-go-go-Related Gene), leading to prolonged cardiac repolarization and increased risk of QTc interval prolongation. Arformoterol, a long-acting beta-2 agonist, can also prolong the QTc interval via beta-adrenergic receptor-mediated effects on cardiac ion channels. Concurrent use may result in additive QTc prolongation, predisposing patients to potentially fatal ventricular arrhythmias such as torsades de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZITHROMYCIN vs BRISTAMYCIN, answered by our medical review team.
AZITHROMYCIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting m RNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.. BRISTAMYCIN is a Macrolide Antibiotic that works by BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZITHROMYCIN and BRISTAMYCIN depend on the specific clinical indication. These are both Macrolide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZITHROMYCIN is: 500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.. The standard adult dose of BRISTAMYCIN is: 500 mg intravenously every 6 hours. Infuse over 60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZITHROMYCIN and BRISTAMYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZITHROMYCIN is classified as Category A/B. FDA Category B. No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No significant association with . BRISTAMYCIN is classified as Category C. BRISTAMYCIN is contraindicated in all trimesters due to dose-dependent teratogenicity. First trimester: high risk of major congenital malformations, including neural tube defects, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.